Login to Your Account

All clear? Aclaris' A-101 'looks approvable' on phase III data, analyst

By Jennifer Boggs
Managing Editor

Wednesday, November 16, 2016

Aclaris Therapeutics Inc. is aiming for a first quarter NDA filing – and a mid-2017 marketing authorization application for seborrheic keratosis on the back of successful results from two phase III trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription